It was found that e.i. circNPM1 could promote the resistance of AML cells to adriamycin via the miR-345-5p/FZD5 axis, indicating that circNPM1 was a potential marker in AML drug resistance therapy [84,85,93]. Here, FZD5 is linked to acute myeloid leukemia.